![](/images/graphics-bg.png)
Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN
Joint Authors
Lai, Hsin-Wen
Young, Kung-Chia
Bai, Chyi-Huey
Yu, Bu-Chin
Lin, Chiou-Feng
Tsao, Chiung-Wen
Chiang, Chiu-Ling
Liao, Chao-Sheng
Chien, Yu-Chieh
Ma, Ching-Ting
Source
Issue
Vol. 2014, Issue 2014 (31 Dec. 2014), pp.1-14, 14 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2014-03-13
Country of Publication
Egypt
No. of Pages
14
Main Subjects
Abstract EN
Peroxisome proliferator-activated receptor gamma (PPARγ) agonist has anti-inflammatory and anticancer properties.
However, the mechanisms by which PPARγ agonist rosiglitazone interferes with inflammation and cancer via phosphatase and tensin homolog-(PTEN)-dependent pathway remain unclear.
We found that lower doses (<25 μM) of rosiglitazone significantly inhibited lipopolysaccharide-(LPS)-induced nitric oxide (NO) release (via inducible nitric oxide synthase, iNOS), prostaglandin E2 (PGE2) production (via cyclooxygenase-2, COX-2), and activation of Akt in RAW 264.7 murine macrophages.
However, rosiglitazone did not inhibit the production of reactive oxygen species (ROS).
In PTEN knockdown (shPTEN) cells exposed to LPS, rosiglitazone did not inhibit NO release, PGE2 production, and activation of Akt.
These cells had elevated basal levels of iNOS, COX-2, and ROS.
However, higher doses (25–100 μM) of rosiglitazone, without LPS stimulation, did not block NO release and PGE2 productions, but they inhibited p38 MAPK phosphorylation and blocked ROS generation in shPTEN cells.
In addition, rosiglitazone caused G1 arrest and reduced the number of cells in S + G2/M phase, leading to growth inhibition.
These results indicate that the anti-inflammatory property of rosiglitazone is related to regulation of PTEN independent of inhibition on ROS production.
However, rosiglitazone affected the dependence of PTEN-deficient cell growth on ROS.
American Psychological Association (APA)
Lin, Chiou-Feng& Young, Kung-Chia& Bai, Chyi-Huey& Yu, Bu-Chin& Ma, Ching-Ting& Chien, Yu-Chieh…[et al.]. 2014. Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN. BioMed Research International،Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-498127
Modern Language Association (MLA)
Lin, Chiou-Feng…[et al.]. Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN. BioMed Research International No. 2014 (2014), pp.1-14.
https://search.emarefa.net/detail/BIM-498127
American Medical Association (AMA)
Lin, Chiou-Feng& Young, Kung-Chia& Bai, Chyi-Huey& Yu, Bu-Chin& Ma, Ching-Ting& Chien, Yu-Chieh…[et al.]. Rosiglitazone Regulates Anti-Inflammation and Growth Inhibition via PTEN. BioMed Research International. 2014. Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-498127
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-498127